# A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People

> **NCT03812198** · PHASE1 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 66 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LEO 32731 modified release tablet
- **DRUG:** LEO 32731 blend, hard capsule
- **DRUG:** LEO 32731 API, hard capsule
- **DRUG:** LEO 32731 soft capsule
- **DRUG:** LEO 32731 gastro-resistant capsule
- **DRUG:** LEO 32731
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03812198
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-22
- **Primary completion:** 2019-06-13
- **Final completion:** 2019-06-13
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2019-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03812198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03812198, "A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03812198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*